🟡 Regulatory Alert
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 3 recall for certain batches of Flucloxacillin Capsules BP 500mg manufactured by Flamingo Pharma UK Ltd, after the company discovered that affected packs contain the Patient Information Leaflet (PIL) for Amoxicillin 500mg Capsules instead of the correct PIL for Flucloxacillin. The recall affects patients who may receive incorrect dosing or allergy guidance if they rely on the mislabelled packaging.
Key takeaways
- Flamingo Pharma UK Ltd identified packs of Flucloxacillin Capsules BP 500mg containing Amoxicillin PIL, according to the MHRA drug safety alert system
- The MHRA classified the recall as Class 3, the lowest severity category but still requiring immediate action
- Patient confusion about medication instructions and potential cross-reactivity between beta-lactam antibiotics poses a safety risk
MHRA Recall Classifications and Risk Levels
Regulatory severity scale for medicines recalls in the United Kingdom
Source: UK MHRA Recall Classification System | Georgian Medical Journal News
What triggered the recall
Flamingo Pharma UK Ltd notified the MHRA that certain batches of Flucloxacillin Capsules BP 500mg sold in the UK market contained packaging with the PIL for Amoxicillin 500mg Capsules. This mismatch creates potential for patient harm if individuals follow amoxicillin-specific guidance when taking flucloxacillin, a related but distinct beta-lactam antibiotic.
Both flucloxacillin and amoxicillin are penicillin-class antibiotics used to treat bacterial infections, but they have different pharmacokinetics, indications, and dosing schedules. Patients relying on incorrect instructions could receive suboptimal treatment or fail to recognise genuine contraindications. The MHRA alert categorises the error as a labelling and packaging defect rather than a product quality issue.
Certain packs of Flucloxacillin Capsules BP 500mg manufactured by Flamingo Pharma UK Ltd contain the Patient Information Leaflet for Amoxicillin 500mg Capsules, creating a labelling error that requires immediate recall.
— UK Medicines and Healthcare products Regulatory Agency (MHRA), 2025
Class 3 classification and patient impact
The MHRA’s Class 3 designation indicates that while a hazard exists, the risk of serious adverse health consequences is remote. However, the classification does not diminish the need for swift action to prevent patient confusion. Affected individuals may not notice the discrepancy between the antibiotic name on the capsule and the instructions on the enclosed leaflet, particularly if they are elderly, have low health literacy, or receive the medication from a pharmacy without additional counselling.
Cross-reactivity between flucloxacillin and amoxicillin is possible in patients with documented penicillin allergy; patients using the wrong PIL could miss critical safety warnings. The recall emphasises the importance of robust pharmacy verification procedures and patient communication at the point of dispensing.
Regulatory and clinical next steps
Flamingo Pharma UK Ltd and the MHRA are coordinating the removal of affected batches from UK pharmacies and wholesalers. Healthcare professionals and patients who have received the affected packs are advised to contact their pharmacy or GP to confirm the correct PIL matches their medication. Quality assurance and packaging integrity remain critical checkpoints in the medicines supply chain to prevent similar errors.
What this means
Frequently asked questions
How do I know if my flucloxacillin pack is affected?
Check whether the Patient Information Leaflet inside your flucloxacillin package mentions amoxicillin instead of flucloxacillin. The MHRA alert provides specific batch numbers and pack identifiers. Contact your pharmacy with the pack details to confirm whether it is part of the recall.
What should I do if I have taken flucloxacillin from an affected pack?
If you have taken doses following the incorrect amoxicillin PIL, contact your GP or pharmacist to clarify the correct flucloxacillin dosing and duration. In most cases, a brief period on slightly different dosing is unlikely to cause harm, but your healthcare provider should review your infection and treatment to ensure adequate coverage.
Are flucloxacillin and amoxicillin interchangeable?
No. While both are penicillin-class antibiotics, flucloxacillin and amoxicillin have different spectra of activity and are used for different types of infections. Flucloxacillin is particularly effective against Staphylococcus aureus, while amoxicillin has broader gram-negative coverage. Using one medication’s instructions for the other can result in suboptimal dosing or missed contraindications.
The MHRA continues to monitor the medicines supply and works with manufacturers to ensure that packaging, labelling, and patient information are accurate and clear. Patients and healthcare professionals are encouraged to report any further issues to the MHRA’s Yellow Card adverse event reporting system to maintain the integrity of the UK medicines safety net.
Source: UK MHRA Class 3 Medicines Recall: Flucloxacillin Capsules BP 500mg, EL(26)A/32
Was this article helpful?
Related Coverage
